Market Research Logo

China Independent Clinical Laboratory Industry Report, 2017-2021

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States and Japan. Furthermore, Chinese independent clinical laboratories can provide more than 2,000 test items, while the counterparts in the United States can offer over 4,000 test items.

However, China's independent clinical laboratory industry is progressing rapidly, presenting the CAGR of 41.4% during 2010-2016, with the market size reaching RMB9.6 billion (an upsurge of 37.1% year on year) in 2016.

Pushed by the promotion of hierarchical medical system and other favorable policies, the growth of the outsourcing demand from public and private hospitals under the pressure of cost control, the acceleration of population aging as well as the people's ever growing awareness of health, etc., the independent clinical laboratory market size in China will maintain growth rate of at least 30% in the next five years and reach RMB41.4 billion by 2021.

As of the end of 2016, there had been 468 independent clinical laboratories in China, an increase of 112 ones over the same period of last year. They were mainly distributed in the developed coastal areas, about 50% of which were located in Shanghai, Beijing, Guangdong, Zhejiang and Jiangsu.

At present, major independent clinical laboratory companies in China include KingMed Diagnostics, ADICON, DIAN Diagnostics, DAAN Gene, Shanghai Labway Clinical Laboraory, MedicalSystem Biotechnology, Beijing Lepu Gene Technology and so forth. With cutting-edge advantages in the number of laboratories and inspection items which directly demonstrate the competitiveness of enterprises, KingMed Diagnostics, ADICON, DIAN Diagnostics and DAAN Gene held a combined market share of over 70% in 2016. In the future, leading enterprises will continue to accelerate the chain-based expansion of laboratory network nationwide, further enhance their competitiveness, and intensify the market concentration.

China Independent Clinical Laboratory Industry Report, 2017-2021 highlights the following:
Overview of China’s independent clinical laboratory industry, covering policy, international environment, status quo, market size, competitive landscape and development trend;
Upstream and downstream sectors of China’s independent clinical laboratory industry;
Operation, revenue structure, gross margin and independent clinical laboratory business of 20 companies in China.

Please Note: PDF E-mail from Publisher purchase option allows up to 10 users and does not allow printing or editing. This functionality will require a Global Site License.

1. Overview of Independent Clinical Laboratory
1.1 Definition
1.2 Industry Chain
2. Overview of China Independent Clinical Laboratory Industry
2.1 Policy Environment
2.1.1 Access Policy
2.1.2 Industry Policy
2.2 International Environment
2.2.1 Status Quo
2.2.2 Benchmarking Enterprises
2.3 Status Quo
2.4 Market size
2.5 Competitive Landscape
2.6 Development Trends
2.6.1 The Industry's Growth Rate Will Be Above 30% in the Next Five Years
2.6.2 Hierarchical Medical System Will Boost the Rapid Development of the Industry
2.6.3 The Laboratory Outsourcing Proportion of Public Hospitals Will Rise due to Cost Control
2.6.4 High-end Test Items Will Make More Revenue Contribution
2.6.5 The Rapid Development of Private Hospitals Will Stimulate the Demand in the Independent Clinical Laboratory Market
2.6.6 Independent Clinical Laboratory Institutions Will Become Technical Leaders amid Quick Technological Upgrades
2.6.7 The Aging Population Balloons and the Demand for Medical Laboratory Will Soar
2.6.8 Internet Will Stimulate the Business Model Upgrade of Independent Clinical Laboratory Industry
3. Upstream and Downstream Sectors of China Independent Clinical Laboratory Industry
3.1 Upstream Sector
3.1.1 Status Quo
3.1.2 Competitive Landscape
3.2 Downstream Sector
3.2.1 Quantity
3.2.2 Medical Services
3.2.3 Revenue
3.2.4 Health Costs
4. Key Players
4.1 KingMed Diagnostics
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D and Investment
4.1.6 Major Customers
4.1.7 Independent Clinical Laboratory Business
4.1.8 Forecast and Outlook
4.2 DIAN Diagnostics
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D and Investment
4.2.6 Independent Clinical Laboratory Business
4.2.7 Forecast and Outlook
4.3 Shanghai Labway Clinical Laboratory
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Independent Clinical Laboratory Business
4.3.7 Forecast and Outlook
4.4 DAAN Gene
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 R&D and Investment
4.4.5 Major Customers
4.4.6 Independent Clinical Laboratory Business
4.4.7 Forecast and Outlook
4.5 ADICON Clinical Laboratories
4.5.1 Profile
4.5.2 Independent Clinical Laboratory Business
4.5.3 Developments
4.6 NYMPHAVN Biotechnology
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D and Investment
4.6.6 Independent Clinical Laboratory Business
4.6.7 Forecast and Outlook
4.7 SurExam Biotechnology
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D and Investment
4.7.6 Independent Clinical Laboratory Business
4.7.7 Forecast and Outlook
4.8 MedicalSystem Biotechnology
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D and Investment
4.8.6 Independent Clinical Laboratory Business
4.8.7 Forecast and Outlook
4.9 Beijing Lawke Health Laboratory
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Gross Margin
4.9.5 R&D and Investment
4.9.6 Forecast and Outlook
4.10 Beijing Lepu Gene Technology
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Gross Margin
4.10.5 R&D and Investment
4.10.6 Major Customers
4.10.7 Forecast and Outlook
4.11 Shanghai Biotecan Pharmaceuticals
4.11.1 Profile
4.11.2 Operation
4.11.3 Revenue Structure
4.11.4 Gross Margin
4.11.5 Independent Clinical Laboratory Business
4.11.6 Forecast and Outlook
4.12 Jiangsu Superbio Life Science
4.12.1 Profile
4.12.2 Operation
4.12.3 Revenue Structure
4.12.4 Gross Margin
4.12.5 Forecast and Outlook
4.13 Amoy Diagnostics
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 Independent Clinical Laboratory Business
4.13.6 Forecast and Outlook
4.14 Guangdong Hybribio Biotech
4.14.1 Profile
4.14.2 Operation
4.14.3 Revenue Structure
4.14.4 Gross Margin
4.14.5 Independent Clinical Laboratory Business
4.14.6 Forecast and Outlook
4.15 Other Enterprises
4.15.1 Kindstar Global
4.15.2 CapitalBio Corporation
4.15.3 Beijing Adinovo Gene Technology Co., Ltd.
4.15.4 Deyi Diagnostics
4.15.5 IPE Center for Clinical Laboratory
4.15.6 Centre Testing International Group Co., Ltd. (CTI)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report